{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2005"],"condition":["Metastatic Colorectal Cancer","Colorectal Neoplasms","first-line therapy in patients with metastatic colorectal cancer"],"disease":["Metastatic Colorectal Cancer","Colorectal Neoplasms","First-line Therapy In Patients With Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2025943"],"location":["Romania","Cyprus","Hungary","Czechia","Portugal","Austria","Turkey","Israel","Slovakia","Slovenia","Bulgaria","Bosnia and Herzegovina","Croatia"],"study_start_month":["7"],"keyword":["Irinotecan","Oxaliplatin","Leucovorin","FOLFOX 6","Cetuximab","FOLFIRI"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer","description":"In Patients with metastatic colorectal cancer the following treatments first-line Folfiri+Cetuximab first-line Folfox6 + Cetuximab will be concerning efficacy and safety.\nThe trial compares Folfiri + Cetuximab and Folfox6 + Cetuximab concerning efficacy and safety as first","dates":{"creation":"2005-07-15"},"accession":"2025943","cross_references":{"ClinicalTrials___gov":["NCT00286130"],"EU Clinical Trials Register":["2004-002391-42"]}}